{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:37:35Z","timestamp":1787027855476,"version":"build-2736575974"},"reference-count":118,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Romanian Ministry of Research, Innovation and Digitalization (Bursa Henri Coand\u0103)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Advances in molecular biology, polymerase chain reaction (PCR), and next-generation sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a philosophical idea into a measurable reality. Current Treatment Paradigms and Lessons Learned from APL: Acute promyelocytic leukemia (APL) leads the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies. Along the way, we have gained valuable insights that, when applied to other forms of acute leukemia, hold the potential to significantly improve the outcomes of these challenging diseases. Does the BM Microenvironment Play a Role in MRD?: In this review, we explore the current use of MRD in the management of acute leukemia and delve into the biological processes that contribute to MRD persistence, including its overlap with leukemia stem cells and the role of the bone marrow microenvironment.<\/jats:p>","DOI":"10.3390\/cancers16183208","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T07:38:57Z","timestamp":1726817937000},"page":"3208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6252-6281","authenticated-orcid":false,"given":"David","family":"Kegyes","sequence":"first","affiliation":[{"name":"MedFuture Research Center for Advanced Medicine, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"},{"name":"The Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveena S.","family":"Thiagarajan","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3955-7944","authenticated-orcid":false,"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"ref_1","unstructured":"Veith, I. (1966). The Yellow Emperor\u2019s Classic of Internal Medicine, University of California Press."},{"key":"ref_2","unstructured":"Avicenna (1930). A Treatise on the Canon of Medicine of Avicenna, Luzac & Co."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1086\/368701","article-title":"The Reception of Fracastoro\u2019s Theory of Contagion: The Seed That Fell among Thorns?","volume":"6","author":"Nutton","year":"1990","journal-title":"Osiris"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2013-01-480590","article-title":"MRD in AML: Time for redefinition of CR?","volume":"121","author":"Ossenkoppele","year":"2013","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0145-2126(81)90002-3","article-title":"Immunological Monitoring of Residual Disease in Treated Thymic Acute Lymphoblastic Leukaemia","volume":"5","author":"Bradstock","year":"1981","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in Adults: 2024 ELN Recommendations from a European Expert Panel","volume":"143","author":"Boissel","year":"2024","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute Myeloid Leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood Acute Lymphoblastic Leukemia: Progress through Collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted by Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bjh.18709","article-title":"Venetoclax plus \u201c2 + 5\u201d Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated de Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis","volume":"201","author":"Wang","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD Quantification in European ALL Trials: Proceedings of the Second International Symposium on MRD Assessment in Kiel, Germany, 18\u201320 September 2008","volume":"24","author":"Schrauder","year":"2010","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00277-018-3230-z","article-title":"Minimal Residual Disease (MRD) Detection Using Rearrangement of Immunoglobulin\/T Cell Receptor Genes in Adult Patients with Acute Lymphoblastic Leukemia (ALL)","volume":"97","author":"Shahkarami","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving Treatment-Free Remission into Mainstream Clinical Practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","article-title":"Clinical Implications of Sequential MRD Monitoring by NGS at 2 Time Points after Chemotherapy in Patients with AML","volume":"5","author":"Tsai","year":"2021","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/Measurable Residual Disease in AML: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for Minimal Residual Disease in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-023-00941-4","article-title":"Risk-Directed Therapy Based on Genetics and MRD Improves the Outcomes of AML1-ETO-Positive AML Patients, a Multi-Center Prospective Cohort Study","volume":"13","author":"Xu","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.3324\/haematol.2014.114579","article-title":"Minimal Residual Disease Monitored after Induction Therapy by RQ-PCR Can Contribute to Tailor Treatment of Patients with t(8;21) RUNX1-RUNX1T1 Rearrangement","volume":"100","author":"Pigazzi","year":"2014","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-Directed Risk Stratification Treatment May Improve Outcomes of t(8;21) AML in the First Complete Remission: Results from the AML05 Multicenter Trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41375-022-01738-3","article-title":"Impact of Pre-Transplant Induction and Consolidation Cycles on AML Allogeneic Transplant Outcomes: A CIBMTR Analysis in 3113 AML Patients","volume":"37","author":"Boyiadzis","year":"2022","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hu, G.-H., Cheng, Y.-F., Lu, A.-D., Wang, Y., Zuo, Y.-X., Yan, C.-H., Wu, J., Sun, Y.-Q., Suo, P., and Chen, Y.-H. (2020). Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Prognosis of High-Risk Pediatric t(8;21) Acute Myeloid Leukemia in First Remission Based on MRD-Guided Treatment. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07043-5"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in Patients with FLT3-Mutated Relapsed\/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia with Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bercier, P., and De Th\u00e9, H. (2024). History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies. Cancers, 16.","DOI":"10.3390\/cancers16071351"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kayser, S., and Conneely, S.E. (2023). Management of Acute Promyelocytic Leukemia at Extremes of Age. Cancers, 15.","DOI":"10.3390\/cancers15143637"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gill, H., Raghupathy, R., Lee, C.Y.Y., Yung, Y., Chu, H.-T., Ni, M.Y., Xiao, X., Flores, F.P., Yim, R., and Lee, P. (2023). Acute Promyelocytic Leukaemia: Population-Based Study of Epidemiology and Outcome with ATRA and Oral-ATO from 1991 to 2021. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10612-z"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hermsen, J., and Hambley, B. (2023). The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management. Cancers, 15.","DOI":"10.3390\/cancers15133477"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cyto.b.22085","article-title":"Acute Promyelocytic Leukemia: Immunophenotype and Differential Diagnosis by Flow Cytometry","volume":"102","author":"Fang","year":"2022","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"992","DOI":"10.18632\/oncotarget.27513","article-title":"Acute Promyelocytic Leukemia (APL): A Review of the Literature","volume":"11","author":"Jimenez","year":"2020","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2293513","DOI":"10.1080\/16078454.2023.2293513","article-title":"Prognosis Influence of Additional Chromosome Abnormalities in Newly Diagnosed Acute Promyelocytic Leukemia with t(15;17)(Q24;Q21)","volume":"29","author":"Liu","year":"2023","journal-title":"Hematology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Li, A.Y., Kashanian, S.M., Hambley, B.C., Zacholski, K., Duong, V.H., Chaer, F.E., Holtzman, N.G., Gojo, I., Webster, J.A., and Norsworthy, K.J. (2021). FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification. Biology, 10.","DOI":"10.3390\/biology10030243"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2141.1986.tb02200.x","article-title":"Features Affecting Outcome during Remission Induction of Acute Myeloid Leukaemia in 619 Adult Patients","volume":"64","author":"Swirsky","year":"1986","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.V56.5.773.773","article-title":"Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia","volume":"56","author":"Mertelsmann","year":"1980","journal-title":"Blood"},{"key":"ref_39","first-page":"708","article-title":"Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia\u2014Results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance","volume":"6","author":"Morrison","year":"1992","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood.V86.5.1717.bloodjournal8651717","article-title":"Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia","volume":"86","author":"Head","year":"1995","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Nagai, Y., and Ambinder, A.J. (2023). The Promise of Retinoids in the Treatment of Cancer: Neither Burnt out nor Fading Away. Cancers, 15.","DOI":"10.3390\/cancers15143535"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"113451","DOI":"10.1016\/j.ejmech.2021.113451","article-title":"Overview of All-Trans-Retinoic Acid (ATRA) and Its Analogues: Structures, Activities, and Mechanisms in Acute Promyelocytic Leukaemia","volume":"220","author":"Liang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Woods, A.C., and Norsworthy, K.J. (2023). Differentiation Syndrome in Acute Leukemia: APL and Beyond. Cancers, 15.","DOI":"10.3390\/cancers15194767"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia","volume":"72","author":"Huang","year":"1988","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10428190500463932","article-title":"Single-Agent Liposomal All-Trans Retinoic Acid Can Cure Some Patients with Untreated Acute Promyelocytic Leukemia: An Update of the University of Texas M. D. Anderson Cancer Center Series","volume":"47","author":"Tsimberidou","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1073\/pnas.89.7.2694","article-title":"Reverse Transcription Polymerase Chain Reaction for the Rearranged Retinoic Acid Receptor Alpha Clarifies Diagnosis and Detects Minimal Residual Disease in Acute Promyelocytic Leukemia","volume":"89","author":"Miller","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/0140-6736(92)92625-P","article-title":"Molecular Evaluation of Residual Disease as a Predictor of Relapse in Acute Promyelocytic Leukaemia","volume":"340","author":"Diverio","year":"1992","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute Promyelocytic Leukemia: From Highly Fatal to Highly Curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"ref_49","first-page":"61","article-title":"Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse","volume":"10","author":"Grimwade","year":"1996","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V92.3.784","article-title":"Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML\/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter \u201cAIDA\u201d trial","volume":"92","author":"Diverio","year":"1998","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1182\/blood.V94.7.2225.419k03_2225_2229","article-title":"Therapy of molecular relapse in acute promyelocytic leukemia","volume":"94","author":"Diverio","year":"1999","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","article-title":"Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy","volume":"27","author":"Grimwade","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_53","first-page":"243","article-title":"Studies on the clinical practice and mechanisms of 713 (As2O3) in the treatment of 117 cases of APL","volume":"29","author":"Zhang","year":"1995","journal-title":"J. Harbin Med. Univ."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","article-title":"Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Durable Remissions with Minimal Toxicity","volume":"107","author":"Mathews","year":"2006","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ncb1717","article-title":"Arsenic Degrades PML or PML\u2013RAR\u03b1 through a SUMO-Triggered RNF4\/Ubiquitin-Mediated Pathway","volume":"10","author":"Jeanne","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/febs.17041","article-title":"Mutations at Proximal Cysteine Residues in PML Impair ATO Binding by Destabilizing the RBCC Domain","volume":"291","author":"Dubey","year":"2023","journal-title":"FEBS J."},{"key":"ref_57","first-page":"3345","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells","volume":"89","author":"Chen","year":"1997","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"29989","DOI":"10.1074\/jbc.M109.090530","article-title":"Autophagy Is a Critical Mechanism for the Induction of the Antileukemic Effects of Arsenic Trioxide","volume":"285","author":"Goussetis","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12272-023-01481-y","article-title":"Arsenic Trioxide: Applications, Mechanisms of Action, Toxicity and Rescue Strategies to Date","volume":"47","author":"Yan","year":"2023","journal-title":"Arch. Pharmacal Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic Trioxide and All-Trans Retinoic Acid Treatment for Acute Promyelocytic Leukaemia in All Risk Groups (AML17): Results of a Randomised, Controlled, Phase 3 Trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective Treatment of Acute Promyelocytic Leukemia with All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia","volume":"369","author":"Avvisati","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-Adapted Treatment of Acute Promyelocytic Leukemia with All-Trans-Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group","volume":"103","author":"Sanz","year":"2003","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.58.4.1468","article-title":"Clonal Origin of Chronic Myelocytic Leukemia in Man","volume":"58","author":"Fialkow","year":"1967","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A Cell Initiating Human Acute Myeloid Leukaemia after Transplantation into SCID Mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1084\/jem.20140131","article-title":"Niche Displacement of Human Leukemic Stem Cells Uniquely Allows Their Competitive Replacement with Healthy HSPCs","volume":"211","author":"Boyd","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","article-title":"A Clinically Relevant Population of Leukemic CD34+CD38\u2212 Cells in Acute Myeloid Leukemia","volume":"119","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The Interleukin-3 Receptor Alpha Chain Is a Unique Marker for Human Acute Myelogenous Leukemia Stem Cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 Eradicates Human Acute Myeloid Leukemic Stem Cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 Is a Leukemic Stem Cell-Specific Marker in Human Acute Myeloid Leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The Novel AML Stem Cell\u2013Associated Antigen CLL-1 Aids in Discrimination between Normal and Leukemic Stem Cells","volume":"110","author":"Kelder","year":"2007","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2015-11-683649","article-title":"GPR56 Identifies Primary Human Acute Myeloid Leukemia Cells with High Repopulating Potential In Vivo","volume":"127","author":"Pabst","year":"2016","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.exphem.2016.08.010","article-title":"Translating Leukemia Stem Cells into the Clinical Setting: Harmonizing the Heterogeneity","volume":"44","author":"Yanagisawa","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41467-021-21650-1","article-title":"Identification of Leukemic and Pre-Leukemic Stem Cells by Clonal Tracking from Single-Cell Transcriptomics","volume":"12","author":"Velten","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cyto.a.22628","article-title":"Single-cell Mass Cytometry Reveals Intracellular Survival\/Proliferative Signaling in FLT3-ITD-mutated AML Stem\/Progenitor Cells","volume":"87","author":"Han","year":"2015","journal-title":"Cytom. Part A"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/stem.769","article-title":"Concise Review: Cancer Stem Cells and Minimal Residual Disease","volume":"30","author":"Ghiaur","year":"2011","journal-title":"Stem Cells"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2015.135194","article-title":"Association of Acute Myeloid Leukemias Most Immature Phenotype with Risk Groups and Outcomes","volume":"101","author":"Gerber","year":"2016","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.1990.8.8.1389","article-title":"Prognostic Significance of CD34 Expression in Childhood B-Precursor Acute Lymphocytic Leukemia: A Pediatric Oncology Group Study","volume":"8","author":"Borowitz","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High Levels of CD34+CD38low\/\u2212CD123+ Blasts Are Predictive of an Adverse Outcome in Acute Myeloid Leukemia: A Groupe Ouest-Est Des Leucemies Aigues et Maladies Du Sang (GOELAMS) Study","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.seminhematol.2015.03.003","article-title":"Acute Myelogenous Leukemia and Its Microenvironment: A Molecular Conversation","volume":"52","author":"Ghiaur","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.16456","article-title":"Dissecting the Role of the CXCL12\/CXCR4 Axis in Acute Myeloid Leukaemia","volume":"189","author":"Ladikou","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/leu.2013.256","article-title":"SP\/Drug Efflux Functionality of Hematopoietic Progenitors Is Controlled by Mesenchymal Niche through VLA-4\/CD44 Axis","volume":"28","author":"Malfuson","year":"2013","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: A Key Receptor in the Crosstalk between Tumor Cells and Their Microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"16121","DOI":"10.1073\/pnas.1305937110","article-title":"Regulation of Human Hematopoietic Stem Cell Self-Renewal by the Microenvironment\u2019s Control of Retinoic Acid Signaling","volume":"110","author":"Ghiaur","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Su, M., Alonso, S., Jones, J.W., Yu, J., Kane, M.A., Jones, R.J., and Ghiaur, G. (2015). All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127790"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41375-020-0790-4","article-title":"Overcoming Microenvironment-Mediated Protection from ATRA Using CYP26-Resistant Retinoids","volume":"34","author":"Hernandez","year":"2020","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal Cells Prevent Apoptosis of AML Cells by Up-Regulation of Anti-Apoptotic Proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"138","DOI":"10.20517\/cdr.2022.133","article-title":"Resistance to Energy Metabolism\u2014Targeted Therapy of AML Cells Residual in the Bone Marrow Microenvironment","volume":"6","author":"Tabe","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.18632\/oncotarget.3614","article-title":"Human Bone Marrow Niche Chemoprotection Mediated by Cytochrome P450 Enzymes","volume":"6","author":"Alonso","year":"2015","journal-title":"Oncotarget"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in Bone Marrow Microenvironment\u2013Mediated Protection of FLT3\/ITD AML from Tyrosine Kinase Inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","article-title":"Leukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy","volume":"25","author":"Duan","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-12-784132","article-title":"The Interplay of Leukemia Cells and the Bone Marrow Microenvironment","volume":"131","author":"Duarte","year":"2018","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1111\/jcmm.14298","article-title":"Regulation of Drug Metabolizing Enzymes in the Leukaemic Bone Marrow Microenvironment","volume":"23","author":"Su","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune Escape and Immunotherapy of Acute Myeloid Leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Riether, C. (2022). Regulation of Hematopoietic and Leukemia Stem Cells by Regulatory T Cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1049301"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Cancilla, D., Rettig, M.P., and DiPersio, J.F. (2020). Targeting CXCR4 in AML and ALL. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01672"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"M\u00fcller, L., Tunger, A., Wobus, M., Von Bonin, M., Towers, R., Bornh\u00e4user, M., Dazzi, F., Wehner, R., and Schmitz, M. (2021). Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.637725"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2017.08.001","article-title":"Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia","volume":"32","author":"Passaro","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch Me If You Can: How AML and Its Niche Escape Immunotherapy","volume":"36","author":"Tettamanti","year":"2021","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A Phase 1\/2 Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory Acute Myeloid Leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1172\/JCI88152","article-title":"Hedgehog and Retinoid Signaling Alters Multiple Myeloma Microenvironment and Generates Bortezomib Resistance","volume":"126","author":"Alonso","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/bjh.18783","article-title":"Oral Azacitidine Modulates the Bone Marrow Microenvironment in Patients with Acute Myeloid Leukaemia in Remission: A Subanalysis from the QUAZAR AML-001 Trial","volume":"201","author":"Menezes","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41375-018-0360-1","article-title":"Immune Cell Constitution in Bone Marrow Microenvironment Predicts Outcome in Adult ALL","volume":"33","author":"Hohtari","year":"2019","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sendker, S., Reinhardt, D., and Niktoreh, N. (2021). Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13061423"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","article-title":"Targeting the Innate Immune System in Pediatric and Adult AML","volume":"38","author":"Perzolli","year":"2024","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-Specific Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity against Human Acute Myeloid Leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T Cells Expressing CD123-Specific Chimeric Antigen Receptors Exhibit Specific Cytolytic Effector Functions and Antitumor Effects against Human Acute Myeloid Leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"103984","DOI":"10.1016\/j.critrevonc.2023.103984","article-title":"Real-World Experience with CPX-351 in High-Risk Acute Myeloid Leukemia","volume":"185","author":"Lemoli","year":"2023","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Ambinder, A.J., Norsworthy, K., Hernandez, D., Palau, L., Paun, B., Duffield, A., Chandraratna, R., Sanders, M., Varadhan, R., and Jones, R.J. (2020). A Phase 1 Study of IRX195183, a RARA-Selective CYP26 Resistant Retinoid, in Patients with Relapsed or Refractory AML. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.587062"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","article-title":"Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RAR\u03b1 Agonist, Is a Novel Approach in AML","volume":"7","author":"Cluzeau","year":"2023","journal-title":"Blood Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.13607","article-title":"Tamibarotene in Patients with Acute Promyelocytic Leukaemia Relapsing after Treatment with All-trans Retinoic Acid and Arsenic Trioxide","volume":"171","author":"Sanford","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kegyes, D., Milea, P.A., Mazga, A.-I., Tigu, A.-B., Nistor, M., Cenariu, D., Tomai, R., Buruiana, S., Einsele, H., and T\u0103nase, A.D. (2024). Looking Ahead to Targeting Macrophages by CAR T- or NK-Cells in Blood Cancers. Expert Opin. Ther. Targets, 1\u20139.","DOI":"10.1080\/14728222.2024.2400075"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1568009619666191021122006","article-title":"Novel Mechanistic Insights into the Anti-Cancer Mode of Arsenic Trioxide","volume":"20","author":"Wahiduzzaman","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Moosavi, M.A., and Djavaheri-Mergny, M. (2019). Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143559"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1006822107","article-title":"Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector","volume":"107","author":"Kim","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/18\/3208\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:00:56Z","timestamp":1760112056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/18\/3208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":118,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cancers16183208"],"URL":"https:\/\/doi.org\/10.3390\/cancers16183208","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]}}}